Skip to content
  • Home
  • Discovering Seelos
    • Our Focus
    • Our Seelos Management Team
    • Our Board of Directors
    • Careers
  • Pipeline
    • SLS-002 (intranasal ketamine)
      • Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) 
    • SLS-003 (sublingual ketamine)
    • SLS-004 (gene therapy)
    • SLS-005 (trehalose)
    • SLS-007 (peptidic inhibitor)
  • Patients and Caregivers
  • Investors and Media
    • Overview and Financials
    • Corporate Governance
    • Press Releases
    • SEC Filings
    • Stock Information
  • Home
  • Discovering Seelos
    • Our Focus
    • Our Seelos Management Team
    • Our Board of Directors
    • Careers
  • Pipeline
    • SLS-002 (intranasal ketamine)
      • Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) 
    • SLS-003 (sublingual ketamine)
    • SLS-004 (gene therapy)
    • SLS-005 (trehalose)
    • SLS-007 (peptidic inhibitor)
  • Patients and Caregivers
  • Investors and Media
    • Overview and Financials
    • Corporate Governance
    • Press Releases
    • SEC Filings
    • Stock Information

Month: March 2022

March 10, 2022: HEALEY ALS Platform Trial Weekly Q&A Webinar with Warren Wasiewski, MD of Seelos Therapeutics and Shafeeq Ladha, MD, Regimen E Co-Lead, discussing the science behind trehalose (SLS-005) 

March 12, 2022
Recent Posts
  • Fireside Chat Replay from B. Riley Securities’ Virtual Neuro and Ophthalmology Conference on 4/27/2022
  • Fireside Chat Replay: Current Treatment of Acute Suicidal Ideation and Behavior and Discussion on the Market Potential for Seelos Therapeutics’ SLS-002 Program from 4/25/2022
  • March 10, 2022: HEALEY ALS Platform Trial Weekly Q&A Webinar with Warren Wasiewski, MD of Seelos Therapeutics and Shafeeq Ladha, MD, Regimen E Co-Lead, discussing the science behind trehalose (SLS-005) 
Archives
  • April 2022
  • March 2022
  • October 2021
  • June 2021
  • April 2019
  • March 2019
  • February 2019
  • December 2018

Navigation

  • Home
  • Privacy Policy
  • Terms of Use
  • Accessibility
  • Contact Seelos
  • Sitemap

Recent Posts

  • Fireside Chat Replay from B. Riley Securities’ Virtual Neuro and Ophthalmology Conference on 4/27/2022
  • Fireside Chat Replay: Current Treatment of Acute Suicidal Ideation and Behavior and Discussion on the Market Potential for Seelos Therapeutics’ SLS-002 Program from 4/25/2022

Contact Us

  • Email
    info@seelostx.com
  • Address
    300 Park Avenue
    New York, NY 10022

Follow Us

© 2022 . Built using WordPress and EmpowerWP Theme.